Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
Overreliance on short-acting β2-agonists (SABA) has been a common feature of asthma management globally for at least 30 years. However, given the evidence against the long-term use of SABA, including potentially increased risk of exacerbations, emergency room visits, overall healthcare resource utilization, and mortality, the latest Global Initiative for Asthma report no longer recommends SABA only therapy. Since 2014, we implemented an ICS-containing reliever strategy at our asthma center at the G Baigorria Hospital in Argentina; we only administered budesonide/formoterol via a single inhaler... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Reihe/Periodikum: | European Clinical Respiratory Journal, Vol 9, Iss 1 (2022) |
Verlag/Hrsg.: |
Taylor & Francis Group
|
Schlagwörter: | Asthma management / exacerbations / hospitalizations / Short-acting beta2 agonists / Diseases of the respiratory system / RC705-779 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26894692 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1080/20018525.2022.2110706 |